Antengene
Dr. Jay Mei, founder of Antengene, previously served as the Global Clinical Lead of Clinical Development at Celgene Corporation. Dr. Mei has over 25 years of experience in the clinical development of oncology therapeutics globally and successfully led the development of multiple oncology products, including REVLIMID® in China, which received NDA approval in China and launched in 2013. Outside of the China market, Dr. Mei was responsible for the clinical trials of REVLIMID®, IDHIFA®, etc., in more than 30 countries.
This person is not in any offices
Antengene
Driven by its vision of “Treating Patients Beyond Borders”, Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world.